Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

152 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Opportunistic skeletal muscle metrics as prognostic tools in metastatic castration-resistant prostate cancer patients candidates to receive Radium-223.
Bauckneht M, Lai R, D'Amico F, Miceli A, Donegani MI, Campi C, Schenone D, Raffa S, Chiola S, Lanfranchi F, Rebuzzi SE, Zanardi E, Cremante M, Marini C, Fornarini G, Morbelli S, Piana M, Sambuceti G. Bauckneht M, et al. Among authors: fornarini g. Ann Nucl Med. 2022 Apr;36(4):373-383. doi: 10.1007/s12149-022-01716-w. Epub 2022 Jan 19. Ann Nucl Med. 2022. PMID: 35044592 Free PMC article.
Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy.
International Prognostic Factors Study Group; Lorch A, Beyer J, Bascoul-Mollevi C, Kramar A, Einhorn LH, Necchi A, Massard C, De Giorgi U, Fléchon A, Margolin KA, Lotz JP, Germa Lluch JR, Powles T, Kollmannsberger CK. International Prognostic Factors Study Group, et al. J Clin Oncol. 2010 Nov 20;28(33):4906-11. doi: 10.1200/JCO.2009.26.8128. Epub 2010 Oct 18. J Clin Oncol. 2010. PMID: 20956623
Contrast-enhanced [18 F] fluorodeoxyglucose-positron emission tomography/computed tomography in clinical oncology: tumor-, site-, and question-based comparison with standard positron emission tomography/computed tomography.
Morbelli S, Conzi R, Campus C, Cittadini G, Bossert I, Massollo M, Fornarini G, Calamia I, Marini C, Fiz F, Ghersi C, Derchi LE, Sambuceti G. Morbelli S, et al. Among authors: fornarini g. Cancer Imaging. 2014 Apr 22;14(1):10. doi: 10.1186/1470-7330-14-10. Cancer Imaging. 2014. PMID: 25609564 Free PMC article.
Enzalutamide in Castration-Resistant Prostate Cancer.
Bregni G, Rebuzzi SE, Fornarini G. Bregni G, et al. Among authors: fornarini g. N Engl J Med. 2018 Oct 4;379(14):1380-1. doi: 10.1056/NEJMc1810065. N Engl J Med. 2018. PMID: 30284801 No abstract available.
Cabozantinib-related cardiotoxicity: a prospective analysis in a real-world cohort of metastatic renal cell carcinoma patients.
Iacovelli R, Ciccarese C, Fornarini G, Massari F, Bimbatti D, Mosillo C, Rebuzzi SE, Di Nunno V, Grassi M, Fantinel E, Ardizzoni A, Tortora G. Iacovelli R, et al. Among authors: fornarini g. Br J Clin Pharmacol. 2019 Jun;85(6):1283-1289. doi: 10.1111/bcp.13895. Epub 2019 Mar 31. Br J Clin Pharmacol. 2019. PMID: 30740760 Free PMC article.
Plasma AR status and cabazitaxel in heavily treated metastatic castration-resistant prostate cancer.
Conteduca V, Castro E, Wetterskog D, Scarpi E, Jayaram A, Romero-Laorden N, Olmos D, Gurioli G, Lolli C, Sáez MI, Puente J, Schepisi G, Salvi S, Wingate A, Medina A, Querol-Niñerola R, Marin-Aguilera M, Arranz JA, Fornarini G, Basso U, Mellado B, Gonzalez-Billalabeitia E, Attard G, De Giorgi U. Conteduca V, et al. Among authors: fornarini g. Eur J Cancer. 2019 Jul;116:158-168. doi: 10.1016/j.ejca.2019.05.007. Epub 2019 Jun 11. Eur J Cancer. 2019. PMID: 31200322
Role of Baseline and Post-Therapy 18F-FDG PET in the Prognostic Stratification of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated with Radium-223.
Bauckneht M, Capitanio S, Donegani MI, Zanardi E, Miceli A, Murialdo R, Raffa S, Tomasello L, Vitti M, Cavo A, Catalano F, Mencoboni M, Ceppi M, Marini C, Fornarini G, Boccardo F, Sambuceti G, Morbelli S. Bauckneht M, et al. Among authors: fornarini g. Cancers (Basel). 2019 Dec 20;12(1):31. doi: 10.3390/cancers12010031. Cancers (Basel). 2019. PMID: 31861942 Free PMC article.
Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDIa study.
Bersanelli M, Buti S, Banna GL, De Giorgi U, Cortellini A, Rebuzzi SE, Tiseo M, Fornarini G, Mazzoni F, Panni S, De Tursi M, Di Marino P, Rossetti S, Rossi E, Tomao S, De Luca E, Sorarù M, Mucciarini C, Atzori F, La Torre L, Vitale MG, Martelli V, Sepe P, Mollica V, Vaccaro V, Schinzari G, Ficorella C, Massari F, Maestri A, Sabbatini R, Sava T, Di Maio M, Verzoni E, Procopio G, Giannarelli D. Bersanelli M, et al. Among authors: fornarini g. Immunotherapy. 2020 Feb;12(2):151-159. doi: 10.2217/imt-2019-0180. Immunotherapy. 2020. PMID: 32089035
Incidence and outcomes of severe acute respiratory syndrome coronavirus 2 infection in patients with metastatic castration-resistant prostate cancer.
Caffo O, Gasparro D, Di Lorenzo G, Volta AD, Guglielmini P, Zucali P, Bortolus R, Cavo A, Ceresoli G, Chiari R, Fornarini G, Fratino L, Iaculli A, Maruzzo M, Masini C, Morelli F, Mucciarini C, Procopio G, Sabbatini R, Verri E, Kinspergher S, Maines F, Messina C, Veccia A, Donini M. Caffo O, et al. Among authors: fornarini g. Eur J Cancer. 2020 Nov;140:140-146. doi: 10.1016/j.ejca.2020.09.018. Epub 2020 Oct 20. Eur J Cancer. 2020. PMID: 33091718 Free PMC article.
152 results